Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Laronde is a biotechnology company, founded by Flagship Pioneering, that is developing Endless RNA™ (eRNA), a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body. This platform technology aims to create a new class of medicines with the potential for long-lasting and tunable protein expression, offering a versatile approach to treat a wide range of diseases. Laronde's mission is to dramatically improve the lives of patients by leveraging the unique therapeutic potential of eRNA. After a period of significant funding and expansion, the company underwent restructuring in 2023 to focus its strategy and appointed a new CEO in mid-2024 to lead its next phase.
Serves as the primary center for Laronde's research and development of its eRNA platform, as well as corporate operations, strategic planning, and business development.
The headquarters is situated in a modern life sciences building, likely equipped with state-of-the-art laboratory facilities for advanced RNA research, development, and analytics, alongside collaborative office environments designed to foster innovation.
Laronde aims to cultivate a dynamic, scientifically-driven, and collaborative work environment. The culture emphasizes cutting-edge research, innovation, and a collective focus on translating scientific breakthroughs into impactful medicines for patients. Recent restructuring may have impacted the internal culture, with a renewed focus under new leadership.
Its Cambridge location provides Laronde with unparalleled access to a rich ecosystem of academic institutions, research talent, potential collaborators, and venture capital, all crucial for advancing its pioneering eRNA technology.
While Laronde's physical operations and headquarters are based in the United States (Cambridge, MA), its scientific research and the potential applications of its eRNA therapeutics have a global scope. The company aims to develop medicines for diseases that affect patients worldwide. Future activities, such as clinical trials and potential partnerships, may extend its operational reach internationally as its therapeutic candidates advance.
325 Binney St
Cambridge
Massachusetts
USA
Address: Operations are primarily centralized at the Cambridge, MA headquarters.
Centralization supports focused execution on its eRNA platform and leverages the rich biotech ecosystem of Cambridge.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Laronde' leadership includes:
Laronde has been backed by several prominent investors over the years, including:
Laronde has undergone significant leadership transitions in the past 12-18 months, including the appointment of a new CEO in June 2024 and a new CSO in July 2023. These changes followed departures in key executive roles as the company restructured and refocused its strategic priorities.
Discover the tools Laronde uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Laronde likely utilizes standard corporate email formats. Common patterns for companies of its type include using the first initial followed by the last name, or first name separated from the last name by a period, at their company domain.
`f[last]@laronde.bio` (e.g., jdoe@laronde.bio) and `[first].[last]@laronde.bio` (e.g., jane.doe@laronde.bio)
Format
jdoe@laronde.bio
Example
75%
Success rate
GlobeNewswire • June 3, 2024
Laronde announced the appointment of Amit Munshi as its new Chief Executive Officer, effective June 3, 2024. Mr. Munshi, an experienced biopharmaceutical executive, is expected to lead Laronde in advancing its eRNA platform....more
GlobeNewswire • July 27, 2023
Laronde announced the appointment of Pengcheng Zhu, Ph.D., as its Chief Scientific Officer. Dr. Zhu brings extensive experience in RNA biology and drug development to lead Laronde's research and discovery efforts....more
Fierce Biotech • August 2, 2023
Reports emerged that Laronde was undergoing a significant restructuring, including layoffs, as part of a strategic refocus of its eRNA platform. This occurred around the time of a CSO transition, signaling a shift in its research and development priorities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Laronde, are just a search away.